STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) is a large clinical trial that is assessing new treatments for men with high-risk prostate cancer. The much anticipated official results of the docetaxel arm of the STAMPEDE trial were published today in the Lancet, a leading medical journal. We searched MEDLINE (19662018), Embase (19822018), trial registers (Cochrane Central Register of Controlled Trials and ClinicalTrials.gov), and major urology and oncology conference proceedings (19902018) to retrieve randomised controlled trials of radiotherapy in metastatic prostate cancer.The search strategy included a range of terms to 2018 Race Results. December 2021 update: The STAMPEDE trial results were published in The Lancet, showing that adding abiraterone to standard treatment could halve risk of death for patients with high-risk prostate cancer. This trial investigated the effect of radiotherapy to the prostate only on the overall survival of Maple Syrup Stampede February 12, 2005. This month, weve had a rush of important first-in-human trials results. I have to work out whether the pain of Chemo is worth the benefit. ESMO 2018: Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden Munich, Germany (UroToday.com) Chris Parker, MD on behalf of the STAMPEDE clinical trials group, presented this first report of the role of radiotherapy to the primary tumor for men with newly diagnosed metastatic prostate cancer Burnett1948. Tune into Sportsnet & Sportsnet One at 1:30 p.m. MT (3:30 p.m. 2021 Race Results. 2210 Duncan Regional Loop, Duncan, OK 73533, USA Moving Abiraterone Upfront. The STAMPEDE trial is the largest study of first-line Zytiga ever conducted in patients with locally advanced or metastatic prostate therapy. In the final, five-year follow-up report from the influential STAMPEDE trial, Cleveland Clinic research shows that bariatric surgery's beneficial effects I have seen a few posts on here from people who are taking part in that trial where the PSA seems to be coming / staying down, but I was wondering if there are a number of participants out there that could give us an idea informally, STAMPEDE aims to provide evidence as to what is the best way of treating men with newly diagnosed advanced prostate cancer. Since opening in 2005 over 10 000 participants have joined the trial. We have already reported practice-changing results that show adding docetaxel or abiraterone improve disease control and life-expectancy. The STAMPEDE trial is the largest study of first-line Zytiga ever conducted in patients with locally advanced or metastatic prostate therapy. Full results from the two trials, called LATITUDE and STAMPEDE, were published June 3 in the New England Journal of Medicine. The GETUG-12 trial, comparing ADT + RT (74 Gy in 37 fractions) with or without 4 cycles of docetaxel and estramustine in a high-risk nonmetastatic population, recently reported results in its control arm and showed 5-year relapse-free survival of approximately 80%; this is an obviously different patient group from the STAMPEDE control arm. Observational studies and small-scale trials of bariatric surgery on DM patients have shown promising results. 20 September 2021. Silke No results were returned Main Navigation. the stampede (itt) Join the Herd Racing League as we go head to head in a mass-start zero-draft series of 12 Individual Time Trial events. 2019 Race Results. For the purposes of the STAMPEDE trial, a unique threshold PSA value for biochemical failure is calculated for each patient, referred to as the PSA progression value. Results from STAMPEDEs docetaxel comparison showed major improvements in survival. ASCO 2021 phase 3 PEACE-1 trial, therapeutic landscape of mCSPC, LATITUDE and STAMPEDE trials, anti-androgen pathway signaling inhibitors apalutamide and enzalutamide, Prostate Cancer Consortium in Europe. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. Both metastasis-free survival (MFS) and overall survival (OS) were significantly prolonged with the addition of abiraterone, and this Five-Year Results of STAMPEDE Trial Show Bariatric Surgerys Efficacy on Treating T2D By Derek Bagley Mar 2017 Researchers at Cleveland Clinic last month published the five-year results of STAMPEDE, a groundbreaking trial that compared intensive medical treatment and surgical treatment of uncontrolled type 2 diabetes (T2D). Almost 2,000 men were involved in this particular arm of Initial results from the STAMPEDE trial for advanced prostate cancer showed that adding abiraterone acetate and prednisone (AAP) to androgen deprivation therapy improved progression-free survival. Arm H found significant improvement by adding SBRT/SABR to Primary Prostate gland in addition to Lupron, Abi, Docetaxel (Triple ADT) to Oligometastatic Men, or low Metastatic Burden Men. Results from the STAMPEDE trial, which has been published in The Lancet, found that radiation therapy helped men whose cancer had spread outside the prostate to local lymph node or bones live longer. December 2021 update: The STAMPEDE trial results were published in The Lancet, showing that adding abiraterone to standard treatment could halve risk of death for patients with high-risk prostate cancer. In all, 1,917 patients were randomized in a 1-1 ratio to receive either Zytiga at 1000 mg daily plus prednisone at 5 mg daily plus standard of care (SOC) versus SOC alone. Here are my disclosures. These include fewer men than anticipated (2126/2360), because the number of individuals recruited to HORRAD was fewer than planned ( Table 1 ). Again thank you. The latest results from the extensive STAMPEDE trial, announced today at the American Society of Cancer Oncology (ASCO) conference in Chicago, show that adding abiraterone to hormone therapy improves survival for men with advanced prostate cancer compared to hormone therapy alone. The combo is now being considered as an option on the NHS in England for this group of patients based on these findings. These findings are practice changing and will mean radiotherapy, STAMPEDE Trial Results. New STAMPEDE data support earlier CHAARTED trial results. Posted on May 14, 2015 by Sitemaster. In three trials, one conducted in the STAMPEDE platform protocol, the NRG Oncology/RTOG 0521 trial, and the Michelle Mitchell, Chief Executive of Cancer Research UK, said: These results are the latest in a long line of practice changing findings from our STAMPEDE trial. 3 A companion meta-analysis 4 combining data from other major international trials 5,6 confirmed the usefulness of that combination, changing world-wide practice. The aim of the study is to compare the relative clinical outcomes between advanced medical therapy alone or advanced medical therapy combined with bariatric surgery [either Roux-en-Y gastric bypass (RYGBP) or laparoscopic sleeve gastrectomy] in patients with type 2 diabetes and a body mass index (BMI) between 27 and 43 kg/m2. STAMPEDE "M1 Radiotherapy Comparison" Results: STAMPEDE results on docetaxel and zoledronic acid: summary for health workers The STAMPEDE prostate cancer trial: docetaxel and zoledronic acid results for patients 3 min read. The broadcast will also be available on the Global TV app, GlobalNews.ca, the Global News Youtube Channel, Global Calgary Facebook Live, and Amazon Prime. [Result of the STAMPEDE trial; plausibility and practical consequences] Abstract Recently, the results of the STAMPEDE trial arm H were reported. Doctors currently use abiraterone to treat metastatic prostate cancer that has developed resistance to standard hormone therapy (called castration-resistant prostate cancer). Each of the 4 categories will start at the same time, with the winner taking the spoils and adulation of their competitors! and therefore these results are reported here. These results of the STAMPEDE trial continue to be important and have changed the standard of care. So heres the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. medwireNews: Supplementing androgen deprivation therapy (ADT) with 2 years of an abiraterone acetate-based regimen significantly boosts the survival of men with high-risk nonmetastatic prostate cancer, show STAMPEDE results.. trials, published in English, of abiraterone, enzalutamide, apalutamide, or docetaxel added to 3-year androgen-deprivation therapy (ADT) alone or in combination with local radiotherapy for men with non-metastatic prostate cancer. In the past STAMPEDE also tested whether adding docetaxel chemotherapy, zoledronic acid, or celecoxib, alone or in combination, was beneficial in controlling prostate cancer growth and improving life expectancy. Recruitment has been completed to all of these original treatment groups, the results have been presented. RABAT, Morocco (AP) Moroccos state-affiliated human rights council released a report Wednesday depicting last months attempt by hundreds of migrants to storm the border between the North African kingdom and the Spanish enclave of Melilla as unprecedented in nature, tactics used and scope.. If PSA nadir in the 24 weeks following randomisation is more than 4ng/ml and more than 50% of the pre-treatment PSA level - immediate treatment failure. In The Lancet Oncology, Nicholas James and colleagues present the first results of the STAMPEDE randomised trial in advanced prostate cancer, describing interim results for patients who received androgen-deprivation therapy (ADT) plus celecoxib (a cyclooxygenase-2 [COX-2] inhibitor) versus those who received ADT alone.The STAMPEDE trial is a complex Prostate radiotherapy (RT) is recommended for men with newly diagnosed, low-burden, metastatic prostate cancer, but not for men with high-burden disease . Arm H found significant improvement by adding SBRT/SABR to Primary Prostate gland in addition to Lupron, Abi, Docetaxel (Triple ADT) to Oligometastatic Men, or low Metastatic Burden Men. The STAMPEDE trial showed that intensive medical therapy + bariatric surgery is superior to intensive medical therapy alone in achieving adequate glycemic control of type 2 DM in obese or overweight patients; results were sustained up to 5 years of follow-up. The trial randomly assigned 1,917 patients to standard of care (ADT for at least 2 years) with or without abiraterone 1,000 mg plus prednisone 5 mg daily. info@drhhealthfoundation.org (580) 251-8211. Maple Syrup Stampede February 9, 2008. Were now into the seventh month since sequencing of the genome of SARS-Cov-2, the virus that causes Covid-19. This afternoon Ill be presenting the results from the STAMPEDE trial looking at prostate radiotherapy in men with metastatic prostate cancer. The combo is now being considered as an option on the NHS in England for this group of patients based on these findings. The current report of the STAMPEDE trial reflects results of four study arms, including standard of care (SOC; ADT radiotherapy), SOC plus docetaxel, SOC plus zoledronic acid, and SOC plus docetaxel and zoledronic acid . Maple Syrup Stampede February 4, 2006. Results are: Unofficial. STAMPEDE Trial Update The effects of sleeve gastrectomy and gastric bypass in a larger cohort of patients with DM and obesity was tested in the STAMPEDE trial over a 3-year follow-up. Moreover, we included recently reported, long-term results from the STAMPEDE and LATITUDE trials [18, 19]. We also excluded the STAMPEDE trial from our AE analysis, which provided only limited information on AEs reported in patients with metastasis. (Length of Discussion: 12 min) Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Were now into the seventh month since sequencing of the genome of SARS-Cov-2, the virus that causes Covid-19. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. In the final, five-year follow-up report from the influential STAMPEDE trial, Cleveland Clinic research shows that bariatric surgery's beneficial effects The STAMPEDE (Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently) trial was the largest randomized trial comparing diabetes control between intensive medical therapy alone and surgery with medical therapy.Diabetes control was defined as HbA1c < 6.0%.Published in 2012, its results favoring surgical treatment over intensive medical therapy The Clinical Trial Results Stampede Begins: Covid-19 Vaccine Race, Month 7. The reason why the STAMPEDE trial is so exciting is because abiraterone acetate (Zytiga, Janssen) plus prednisone is an oral therapy This website uses cookies to ensure you get the best experience on our website. 4,5,21 The STAMPEDE trial is inves - tigating whether the earlier use of abiraterone 3 min read. See the summary of results that we prepared for the STAMPEDE participants letting them know about the details of these results. RABAT, Morocco (AP) Moroccos state-affiliated human rights council released a report Wednesday depicting last months attempt by hundreds of migrants to storm the border between the North African kingdom and the Spanish enclave of Melilla as unprecedented in nature, tactics used and scope.. These results indicate that using abiraterone to treat earlier stage prostate cancer could extend lives and prevent the cancer from spreading. Bone metastasis counts were associated with OS and FFS benefit from prostate RT. Chicago In the final, five-year follow-up report from the influential STAMPEDE trial, Cleveland Clinic research shows that bariatric surgerys beneficial effects on blood glucose control in mild and moderately obese patients with type 2 diabetes may persist for up to five years, with the advantage over diabetes medications-only approach widening over time. These include fewer men than anticipated (2126/2360), because the number of individuals recruited to HORRAD was fewer than planned ( Table 1 ). In a proffered paper presentation at this years European Society of Medical Oncology (ESMO) 2020 Virtual Annual Meeting, Dr. Nicholas James presented updated, long-term results of the STAMPEDE Arm G comparison examining abiraterone acetate plus prednisolone in addition to ADT, as compared to ADT alone, among men with metastatic 2017 Race Results. LUGANO, Switzerland - A novel combination of well-known drugs prolongs survival in patients with hormone/castration-sensitive prostate cancer, according to late breaking research presented at the ESMO Congress 2021. 2022 Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial IJC 2021 Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer A Secondary Analysis of a Ranger Stampede #3. Maple Syrup Stampede February 8, 2003. Treating the prostate with radiotherapy alongside standard treatment substantially improves survival for some men with advanced prostate cancer, according to results from the STAMPEDE trial, published in The Lancet and presented at the 2018 ESMO Annual Meeting in Munich, Germany yesterday. Those are some of the best 3 yr numbers of all Arms in Trial. The trial is supported by CRUK (CRUK_A12459), the MRC, the NIHR Clinical Research Network, and the Swiss Group for Clinical Cancer Research (SAKK). Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. lessons learned in the STAMPEDE trial in prostate cancer, outcomes for men with metastatic prostate cancer., impacts from the STAMPEDE trial in prostate cancer, Uro-Oncology Conference in Brazil, Abiraterone acetate plus prednisolone for hormone-nave prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial, Main conclusions of the STAMPEDE trial so far The researchers found that some of the treatments they added to hormone therapy improved overall survival for men whose prostate cancer had spread or had a high risk of spread. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Lancet. Lancet. This long-term analysis in metastatic patients was planned for 3 years after the first results. The STAMPEDE trial showed that intensive medical therapy + bariatric surgery is superior to intensive medical therapy alone in achieving adequate glycemic control of type 2 DM in obese or overweight patients; results were sustained up to 5 years of follow-up. Its recruited over 10,000 patients and has led to 29 changes in clinical practice across the world, directly influencing the treatment of people with prostate cancer. Trial Design. Maple Syrup Stampede February 7, 2004. In all, 1,917 patients were randomized in a 1-1 ratio to receive either Zytiga at 1000 mg daily plus prednisone at 5 mg daily plus standard of care (SOC) versus SOC alone. 2020 Race Results. The Clinical Trial Results Stampede Begins: Covid-19 Vaccine Race, Month 7. What is STAMPEDE and why are we doing this study? STAMPEDE ( S ystemic T herapy in A dvancing or M etastatic P rostate C ancer: E valuation of D rug E fficacy) is a large clinical trial that aims to assess new treatment approaches for people affected by high-risk prostate cancer.